“Patients are counting on us, and this remains the best time to be involved in cancer research,” W. Kimryn Rathmell said to The Cancer Letter.
At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, W. Kimryn Rathmell reflected on her decision to take the CEO job at the third largest cancer hospital in the United States.
I did not find the process of being suddenly without employment as refreshing as one might think. It did, however, provide a forced opportunity to engage in self-reflection, to critically analyze the situation around cancer, and to face the complex set of problems that cancer, and society, present to us.
W. Kimryn Rathmell, former director of the NCI, has accepted the role as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Siemens Healthineers and The Ohio State Wexner Medical Center have expanded their existing strategic relationship to form a 10-year, $105 million value partnership to foster breakthroughs in clinical care, in addition to their longstanding research collaboration.
A team at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute completed its first gene therapy for a patient with hemophilia B, the first at an adult medical center in Ohio.
Sir Paul Nurse is the recipient of the 26th Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer. A geneticist and cell biologist who shared the 2001 Nobel Prize in Physiology or Medicine, Nurse is founding director and chief executive officer of the Francis Crick Institute in London.
Christian Rolfo was named director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He will start on Aug. 15.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
A clinic at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Immuno-Oncology Institute aims to help manage the autoimmune side effects of immunotherapy-based cancer treatment and allow patients to live the fullest life possible both during cancer treatment and long-term as a survivor.
